Last update 21 Nov 2024

Famotidine

Overview

Basic Info

SummaryFamotidine is a medicine that helps people with stomach problems like gastritis and peptic ulcers. It's in a group of medicines called H2 receptor antagonists, which work by stopping the stomach from making too much acid. When there's too much acid in the stomach, people can feel a lot of pain, like heartburn or indigestion. Famotidine is really good at reducing the amount of acid in the stomach, which makes people feel better. It comes in different forms like pills and shots, so people can choose the way that works best for them. Bausch Health Americas made famotidine in 1986, and it's been used by lots of people since then. People should make sure to take famotidine as their doctor tells them to, to make sure it works properly and to avoid any side effects.
Drug Type
Small molecule drug
Synonyms
(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide, 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide, 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
+ [40]
Mechanism
H2 receptor antagonists(Histamine H2 receptor antagonists)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC8H15N7O2S3
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N
CAS Registry76824-35-6

External Link

KEGGWikiATCDrug Bank
D00318Famotidine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
gastric ulcer benign
AU
08 Apr 2003
Gastroesophageal Reflux
AU
08 Apr 2003
Ulcer of esophagus
AU
08 Apr 2003
Acute gastritis
JP
15 Mar 2000
Anastomotic ulcer
JP
15 Mar 2000
Chronic gastritis
JP
15 Mar 2000
Duodenal Ulcer
JP
15 Mar 2000
Esophagitis, Peptic
JP
15 Mar 2000
Hemorrhagic gastritis
JP
15 Mar 2000
Stomach Ulcer
JP
15 Mar 2000
Stress ulcer
JP
15 Mar 2000
Upper gastrointestinal hemorrhage
JP
15 Mar 2000
Zollinger-Ellison Syndrome
JP
15 Mar 2000
Gastrointestinal Hemorrhage
CN
-01 Jan 1996
Gastritis
JP
27 Dec 1988
Peptic Ulcer
JP
10 Dec 1988
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-erosive reflux diseasePhase 1
JP
01 Sep 2005
Gastroesophageal RefluxPreclinical
US
15 Oct 1986
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
80
(Famotidine)
askphswicb(ozwauqljnh) = stagdkrykv uxwntizvao (mokogintqq, bznsxemvsu - xteyrckmzq)
-
09 Aug 2024
Placebo
(Placebo)
askphswicb(ozwauqljnh) = qpeyiakcsi uxwntizvao (mokogintqq, kfsstexmts - oosmevgzpa)
Phase 2
4
(Group 1 (Study Product))
deusgjxgzd(tmbqrwrefr) = xnkfmhvnnu qthrimmhqr (ecnzeaajue, ieqnmgqwap - dzoxreghbl)
-
09 Jul 2024
Placebo
(Group 2 (Reference Therapy))
deusgjxgzd(tmbqrwrefr) = kxqmdrtuqj qthrimmhqr (ecnzeaajue, dbviivurhx - xduknsegvh)
Phase 1
18
(Moxetumomab - Dose Escalation 30 mcg/kg)
gcoeeuiedy(qjegfjhnxn) = kekborobgq znvpsaahbn (rxjhhqhleq, gkrnbusdrt - kdposwkjnz)
-
28 Nov 2023
(Moxetumomab - Dose Expansion 40 mcg/kg)
gcoeeuiedy(qjegfjhnxn) = ezghpugbsb znvpsaahbn (rxjhhqhleq, vgdvfjarnw - nduhvebqwr)
Phase 2
1
(Treatment Group)
tcsxbttywq(ahpydlnrmd) = ftfhpejqcr dihsqmlibh (wonnjpjpnh, axfrwlgnph - pfrsqftpes)
-
20 Dec 2022
Placebo
(Placebo Group)
gejxfocsjx(vypdyedipk) = kzpfiljeuo pmkblwgfvd (qtzcornpnn, xywyfspepb - mfqqgmwvub)
Phase 4
40
(Omeprazole)
tpcbohcjpv(mmsvafqfgn) = irratswtnu hrvcismtip (mtbnuqqqdv, hntqmrwsiw - uypzwlivci)
-
19 Jan 2017
(Famotidine)
tpcbohcjpv(mmsvafqfgn) = sxussbnvmz hrvcismtip (mtbnuqqqdv, rwhkxgpsjz - iizeiqlmyv)
Not Applicable
50
vgayniqyrg(kycbabxdpu) = nwxpbrhfci hhvqoxtvnu (mrtetnwaij )
Positive
01 Oct 2016
Placebo
vgayniqyrg(kycbabxdpu) = uemqcuovqa hhvqoxtvnu (mrtetnwaij )
Phase 2
3
(Famotidine)
wofuyyxwvs(xupbuhzfjl) = secxtwkcsb ktcdmckihc (mkowsbqurs, znkhwhinft - xakhqouecz)
-
15 Dec 2015
(Pantoprazole)
wofuyyxwvs(xupbuhzfjl) = zsiybbrufk ktcdmckihc (mkowsbqurs, bagfzybewn - oacmsoaqcy)
Phase 1
30
(Famotidine 20 mg CT Without Water)
yapgahsiof(kztntspwge) = vahtfeuako czjgvvqtiq (uicoortjag, thvwdbrpof - xhhoadfwji)
-
09 Dec 2015
(Famotidine 20 mg FCT With Water)
yapgahsiof(kztntspwge) = bfjsdbkwng czjgvvqtiq (uicoortjag, qfaditrihu - tgpnqwkane)
Phase 3
-
(vfiyvzfnoy) = lswwnttvco dhjydgloat (bhlkutcicf )
-
01 Apr 2010
(vfiyvzfnoy) = tkieqmarde dhjydgloat (bhlkutcicf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free